SRR1080172
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.344
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.306
- OXIDATIVE_PHOSPHORYLATION+0.296
- XENOBIOTIC_METABOLISM+0.296
- COAGULATION+0.281
- ALLOGRAFT_REJECTION+0.249
- INTERFERON_GAMMA_RESPONSE+0.242
- KRAS_SIGNALING_DN+0.219
- FATTY_ACID_METABOLISM+0.184
- CHOLESTEROL_HOMEOSTASIS+0.180
Top 10 suppressed
- G2M_CHECKPOINT-0.543
- E2F_TARGETS-0.452
- MYC_TARGETS_V2-0.427
- MITOTIC_SPINDLE-0.373
- UNFOLDED_PROTEIN_RESPONSE-0.369
- TNFA_SIGNALING_VIA_NFKB-0.315
- MYC_TARGETS_V1-0.306
- TGF_BETA_SIGNALING-0.264
- UV_RESPONSE_DN-0.263
- PROTEIN_SECRETION-0.218
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1419148 | GTEX | — | 0.907 |
| 2 | SRR1399092 | GTEX | — | 0.881 |
| 3 | TCGA-50-6597-01A-11R-1858-07 | — | cohortA1 | 0.875 |
| 4 | SRR1430570 | GTEX | — | 0.860 |
| 5 | ERR2598335 | fetal | fetal | 0.856 |
| 6 | SRR1433600 | GTEX | — | 0.850 |
| 7 | ERR2598328 | fetal | fetal | 0.846 |
| 8 | ERR2598280 | fetal | fetal | 0.841 |
| 9 | SRR1458180 | GTEX | — | 0.838 |
| 10 | ERR2598268 | fetal | fetal | 0.825 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.344 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.306 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.296 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.296 | Inavolisib | — uncovered |
| COAGULATION | 0.281 | Binimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.249 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.242 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.219 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.184 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.180 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.166 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.155 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.149 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.149 | Inavolisib | — uncovered |
| COMPLEMENT | 0.142 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.140 | Idelalisib | — uncovered |
| MYOGENESIS | 0.106 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.089 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.088 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.080 | Inavolisib | — uncovered |